STAT+: Sarepta names Michael Severino, former Tessera CEO, as new chief executive

Sarepta Therapeutics, the beleaguered biotechnology firm known for its Duchenne muscular dystrophy treatments, has appointed Michael Severino as its new chief executive, effective Tuesday. Severino, previously the CEO of Tessera Therapeutics, will take the helm as the company navigates a period of financial decline and mounting pressure from competitors. Severino replaces Doug Ingram, who had led Sarepta for almost a decade before announcing his retirement earlier this year. Under Ingram's leadership, Sarepta secured approvals for three Duchenne therapies, yet the company has been scrutinized for the efficacy of these treatments and has encountered regulatory challenges concerning the safety of its gene therapy products. The recent appointment marks a pivotal shift in the company’s direction amid these ongoing issues. The transition comes as Sarepta's stock price has plummeted since the start of 2025, reflecting investor concerns over the company’s long-term viability. Analysts have pointed to the competitive landscape intensifying, with other firms developing alternative therapies that could potentially offer better outcomes for patients. This backdrop underscores the urgency of the new leadership to stabilize the company and regain market confidence. Michael Severino brings extensive experience in the biopharmaceutical sector, having served as CEO of Tessera Therapeutics, a company focused on genetic disease treatments. His prior role suggests he possesses the strategic acumen needed to address Sarepta's current challenges. However, specifics regarding his plans for the company remain undisclosed, leaving stakeholders to speculate on potential changes in strategy or product development. The decision to appoint Severino follows months of internal restructuring and external pressures. Sarepta has faced criticism not only for the effectiveness of its treatments but also for the transparency surrounding clinical trial data. These factors have contributed to a loss of trust among investors and healthcare professionals alike. As the new CEO takes charge, there is anticipation that he will implement measures aimed at restoring credibility and improving patient outcomes. Looking ahead, the focus will likely shift toward addressing the regulatory hurdles and enhancing the company’s therapeutic offerings. With the biopharma industry evolving rapidly, Sarepta must adapt quickly to maintain relevance and ensure continued support from both investors and patients. The coming months will be critical in determining whether the new leadership can turn the tide and secure a more stable future for the company.